NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response

Novel adjuvants are needed to increase the efficacy of vaccine formulations and immune therapies for cancer and chronic infections. In particular, adjuvants that promote a strong type I IFN response are required, since this cytokine is crucial for the development of efficient anti-tumoral and anti-v...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberson, Anne, Spagnuolo, Lorenzo, Puddinu, Viola, Barchet, Winfried, Rittner, Karola, Bourquin, Carole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814164/
https://www.ncbi.nlm.nih.gov/pubmed/29464024
http://dx.doi.org/10.18632/oncotarget.23725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814164/
https://www.ncbi.nlm.nih.gov/pubmed/29464024
http://dx.doi.org/10.18632/oncotarget.23725

Ejemplares similares